Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Valencia
Clinical trial register · Spain

Clinical Trials in Valencia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Valencia61 AstraZeneca60 Novartis Pharmaceuticals42 Hoffmann-La Roche41 AbbVie39
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Valencia

1215 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Valencia
2020-11-19
Active, closed
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NCT04648202Advanced Cancer, Metastatic Cancer
invoX Pharma Limited
Phase 1
82
Barcelona, Madrid, Valencia
2020-11-18
Active, closed
AstraZeneca
Phase 3
957
Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia
2020-11-17
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Cadiz, Ferrol, Jerez de la Frontera, Madrid, Málaga, Pamplona, Seville, Valencia
2020-11-12
Active, closed
Pfizer
Phase 3
114
Esplugues de Llobregat, Barcelona, Valencia
2020-11-05
Recruiting
University of Valencia
Not applicable
24
Valencia
2020-11-01
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
Madrid, Barcelona, Rioja, Valencia
2020-10-29
Recruiting
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational
500
L'Hospitalet de Llobregat, Barcelona, Valencia
2020-10-28
Active, closed
Hoffmann-La Roche
Phase 3
992
L'Hospitalet de Llobregat, Donostia / San Sebastian, Pozuelo de Alarcón, A Coruña, Barcelona, Madrid, Seville, Valencia
2020-10-09
Recruiting
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
NCT04435990Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
Inmunotek S.L.
Phase 3
150
Santiago de Compostela, Elche, Torrevieja, Valencia, Algeciras, Jerez de la Frontera, Cartagena, Vigo
2020-10-06
Active, closed
AstraZeneca
Phase 3
370
Barcelona, Madrid, Valencia
2020-10-02
Recruiting
University of Birmingham
Phase 1/2
1,672
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Zaragoza
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Barcelona, Cáceres, Madrid, Santander, Seville, Valencia
2020-09-16
Active, closed
AbbVie
Phase 3
531
Badalona, Córdoba, Pozuelo de Alarcón, Barcelona, Madrid, Salamanca, Seville, Valencia
2020-09-10
Active, closed
Philogen S.p.A.
Phase 2
98
Madrid, Málaga, San Cristóbal de La Laguna, San Sebastián, Valencia
2020-08-28
Active, closed
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
DrugsOregovomab·Paraplatin·Taxol·Paclitaxel
CanariaBio Inc.
Phase 3
615
Barcelona, L'Hospitalet de Llobregat, Valencia
2020-08-25
Recruiting
Takeda
Phase 2
160
Barcelona, Salamanca, Seville, Valencia
2020-08-19
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Barcelona, Córdoba, Madrid, Valencia
2020-08-18
Recruiting
Eisai Inc.
Phase 1/2
182
Badalona, Barcelona, Madrid, Toledo, Valencia
2020-08-06
Recruiting
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
University of Siena
Observational
3,500
Barakaldo, Barcelona, Madrid, Santander, Valencia
2020-08-06
Active, closed
MedImmune LLC
Phase 1
67
Barcelona, Córdoba, Madrid, Sabadell, Seville, Valencia
2020-08-05
Active, closed
AstraZeneca
Phase 3
185
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia
2020-08-04
Active, closed
Genentech, Inc.
Phase 1
498
Barcelona, Madrid, Málaga, Seville, Valencia
2020-07-29
Active, closed
Boehringer Ingelheim
Phase 1
306
Barcelona, Pamplona, Valencia
2020-07-29
Active, closed
AstraZeneca
Phase 3
866
A Coruña, Barcelona, Córdoba, El Palmar, Madrid, San Sebastián, Seville, Valencia
2020-07-24
Recruiting
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
NCT03651206Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
DrugNiraparib
ARCAGY/ GINECO GROUP
Phase 2/3
138
Madrid, Murcia, Valencia
2020-07-15
Active, closed
GlaxoSmithKline
Phase 3
242
Barcelona, Madrid, Seville, Valencia
2020-07-14
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Barcelona, Valencia
2020-07-13
Recruiting
Mats Heyman
Phase 3
6,430
Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Palma de Mallorca, Seville, Valencia, Zaragoza
2020-07-13
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Cadiz, Cartagena, Granada, Ourense, Seville, Valencia
2020-07-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Majadahonda, Pozuelo de Alarcón, Málaga, Barcelona, Seville, Valencia
2020-07-06
Recruiting
Normal Pressure Hydrocephalus and Sleep Apnea
NCT04471740Normal Pressure Hydrocephalus, Sleep Apnea, Cerebrospinal Fluid Shunt Occlusion
University of Valencia
Not applicable
30
Valencia
2020-07-02
Active, closed
Sanofi
Phase 3
337
Barcelona, Pamplona, Valencia, Madrid, Salamanca, Zaragoza
2020-06-16
Active, closed
Autolus Limited
Phase 1/2
153
Barcelona, Seville, Valencia
2020-06-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
L'Hospitalet de Llobregat, Valencia, Seville
2020-05-19
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Seville, Valencia
2020-03-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Barcelona, Valencia, Madrid
2020-02-27
Active, closed
Eli Lilly and Company
Phase 3
58
Esplugues de Llobregat, Madrid, Seville, Valencia
2020-02-12
Recruiting
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
DrugPonatinib
Incyte Biosciences International Sàrl
Phase 1/2
70
Barcelona, Madrid, Valencia
2020-01-29
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Badalona, Pamplona, San Cristóbal de La Laguna, Barcelona, Jaén, Madrid, Seville, Valencia
2020-01-29
Recruiting
Eli Lilly and Company
Phase 2
105
Barcelona, Esplugues de Llobregat, Madrid, San Cristóbal de La Laguna, Seville, Valencia
2020-01-22
Active, closed
Takeda
Phase 3
354
L'Hospitalet de Llobregat, A Coruña, Alicante, Barcelona, Córdoba, Madrid, Valencia
2020-01-10
Recruiting
University of Valencia
Not applicable
128
Valencia
2020-01-10
Active, closed
Advanced Accelerator Applications
Phase 3
226
Barcelona, Madrid, Valencia
2020-01-08
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Barcelona, Madrid, Valencia
2019-12-20
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
777
Barcelona, Girona, Lleida, Madrid, Palma, Tarragona, Valencia
2019-12-20
Recruiting
Natural History of Duchenne Muscular Dystrophy
NCT03882827Duchenne Muscular Dystrophy
Genethon
Observational
220
Esplugues de Llobregat, Valencia
2019-12-19
Active, closed
SOLTI Breast Cancer Research Group
Not applicable
180
Badalona, Barcelona, Jerez de la Frontera, Santa Cruz de Tenerife, Lleida, Madrid, Seville, Valencia
2019-12-13
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Barcelona, Madrid, Valencia
2019-12-10
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
DrugLAM561
Laminar Pharmaceuticals
Phase 2/3
144
Córdoba, Seville, Barcelona, Madrid, Valencia, Sabadell
2019-12-01
Active, closed
GlaxoSmithKline
Phase 2
25
Barcelona, Madrid, Valencia
2019-11-28
Active, closed
ETOP IBCSG Partners Foundation
Phase 2
96
Barcelona, Granada, Madrid, Valencia
2019-11-19
Active, closed
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
Universitätsklinikum Hamburg-Eppendorf
Phase 2
167
Badalona, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Palma, Barcelona, Pozuelo de Alarcón, Madrid, Salamanca, Valencia
2019-11-13
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Madrid, Málaga, Oviedo, Seville, Valencia
2019-11-13
Active, closed
Inotrem
Phase 2
355
Barcelona, Madrid, Oviedo, Terrassa, Valencia
2019-11-13
Active, closed
AbbVie
Phase 1/2
218
Madrid, Valencia
2019-11-06
Active, closed
Bristol-Myers Squibb
Phase 3
461
Madrid, Majadahonda - Madrid, Valencia
2019-11-05
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
L'Hospitalet de Llobregat, Seville, Valencia
2019-11-05
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Madrid, Valencia
2019-11-04
Recruiting
Norwegian University of Science and Technology
Phase 3
112
Valencia
2019-11-01
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Pamplona, Valencia
2019-10-31
Active, closed
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
790
Barcelona, A Coruña, Badalona, Madrid, Málaga, Santander, Valencia
2019-10-28
Active, closed
Canadian Cancer Trials Group
Phase 2
82
Barcelona, Madrid, Santander, Valencia
2019-10-25
Active, closed
Replimune, Inc.
Phase 1
36
Barcelona, Madrid, Valencia
2019-10-17
Active, closed
Eli Lilly and Company
Phase 3
30
Esplugues de Llobregat, Madrid, Valencia
2019-10-16
Active, closed
Gilead Sciences
Phase 2
227
Barcelona, Madrid, Valencia
2019-10-15
Recruiting
ALFAOMEGA Master Observational Trial
NCT04120935Colorectal Cancer
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational
3,000
Barcelona, Valencia
2019-10-15
Recruiting
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2
89
Valencia
2019-10-09
Active, closed
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
DrugsVusolimogene Oderparepvec·Cemiplimab
Replimune, Inc.
Phase 2
231
Barcelona, Madrid, Murcia, Pamplona, Valencia
2019-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Palma de Mallorca, Barcelona, San Cristóbal de La Laguna, Córdoba, Madrid, Sant Joan Despí, Seville, Valencia
2019-10-02
Active, closed
University of Zurich
Observational
540
Barcelona, Seville, Valencia
2019-10-01
Active, closed
NeuroDerm Ltd.
Phase 3
381
Oviedo, Alicante, Barcelona, Burgos, Madrid, Seville, Valencia
2019-09-30
Active, closed
RECORDATI GROUP
Observational
125
Barcelona, Valencia
2019-09-30
Active, closed
Celgene
Phase 1/2
424
Badalona, Madrid, Málaga, Pamplona, Salamanca, Santander, Valencia
2019-09-30
By invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
DrugDecitabine
Taiho Oncology, Inc.
Phase 2
332
Lleida, Madrid, Murcia, Valencia
2019-09-30
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Barcelona, Madrid, Valencia
2019-09-23
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Badalona, El Palmar, A Coruña, Barcelona, Córdoba, Seville, Valencia
2019-09-20
Active, closed
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
DrugsZiftomenib·Itraconazole·Midazolam
Kura Oncology, Inc.
Phase 1/2
263
Barcelona, Madrid, Oviedo, Seville, Valencia
2019-09-12
Recruiting
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
NCT04832607AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
Tobias Feuchtinger
Phase 3
149
Barcelona, Madrid, Seville, Valencia
2019-08-27
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Barakaldo, Barcelona, Madrid, Oviedo, Salamanca, Seville, Valencia
2019-08-12
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Pozuelo de Alarcón, El Palmar, Vigo, Barcelona, Madrid, Salamanca, Seville, Valencia
2019-08-12
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Badalona, Barcelona, Madrid, Pamplona, Valencia
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
839
Badalona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia
2019-08-05
Active, closed
OncoVerity, Inc.
Phase 2
103
Pozuelo de Alarcón, Barcelona, Córdoba, Madrid, Palma, Salamanca, Valencia
2019-07-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Badalona, Barcelona, Cáceres, Girona, Pozuelo de Alarcón, Valencia, Madrid, Seville
2019-07-24
Active, closed
Amgen
Phase 3
457
Seville, Barcelona, Pamplona, Valencia
2019-07-19
Recruiting
University of Valencia
Observational
12
Valencia
2019-07-19
Active, closed
Tesaro, Inc.
Phase 3
785
Barcelona, Donostia / San Sebastian, Madrid, Málaga, Murcia, Valencia
2019-07-18
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
197
Badalona, Madrid, Pamplona, Valencia
2019-07-17
Active, closed
Consorzio Futuro in Ricerca
Not applicable
1,445
A Coruña, Ciudad Real, Lugo, Madrid, Santiago de Compostela, Valencia, Valladolid, Vigo
2019-07-15
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Barcelona, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
2019-07-09
Active, closed
Infant Bacterial Therapeutics
Phase 3
2,158
Alicante, Madrid, Tarragona, Valencia
2019-07-04
Active, closed
Grupo Español de Investigación en Cáncer de Ovario
Phase 2
134
Elche, Donostia / San Sebastian, Girona, Madrid, Vigo, Seville, Valencia, Barcelona
2019-06-28
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia
2019-06-26
Active, closed
AstraZeneca
Phase 3
923
Badalona, Barcelona, Hospitalet deLlobregat, Jaén, Madrid, Málaga, Seville, Valencia
2019-06-25
Active, closed
Exelixis
Phase 3
855
Santiago de Compostela, Pamplona, Barcelona, Córdoba, Madrid, Oviedo, Valencia
2019-06-25
Active, closed
AbbVie
Phase 1
124
Esplugues de Llobregat, Madrid, Valencia
2019-06-24
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
366
Barcelona, Lleida, Madrid, Reus, Seville, Valencia
2019-06-14
Recruiting
CSF Protein Markers as Prognostic Indicators of the Response to CSF Shunt in Normotensive Hydrocephalus
NCT05915000Beta-amiloid and Phospho-tau Proteins in CSF, Ventricular Size After CSF Shunt, Cognitive Impairment and CSF Shunt, Motor Impairment Evolution After CSF Shunt
University of Valencia
Observational
150
Valencia
2019-06-13
Active, closed
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Observational
1,508
Santiago de Compostela, Pamplona, Barcelona, Córdoba, Granada, Tarragona, Valencia, Zaragoza
2019-05-27
Active, closed
Novo Nordisk A/S
Phase 3
1,500
A Coruña, Barcelona, L'Hospitalet de Llobregat, Pamplona, Seville, Valencia
2019-05-08
Active, closed
Hospital Universitario Doctor Peset
Phase 2
40
Villajoyosa, Gandia, Valencia
2019-05-01
Recruiting
University of Valencia
Observational
140
Valencia
2019-04-19
Recruiting
Eli Lilly and Company
Phase 3
190
Esplugues de Llobregat, Madrid, Seville, Valencia
2019-04-05
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Majadahonda, Almería, Barcelona, Madrid, Pontevedra, Santander, Seville, Valencia
2019-03-28
Active, closed
AbbVie
Phase 3
964
Badalona, Sabadell, A Coruña, Almería, Barcelona, Madrid, Valencia
2019-03-25
Recruiting
Abbott Medical Devices
Observational
2,000
Salamanca, Majadahonda, Valencia
2019-03-13
Recruiting
Aptose Biosciences Inc.
Phase 1/2
240
Barcelona, Pozuelo de Alarcón, Oviedo, Valencia
2019-03-11
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Barcelona, Girona, Madrid, Palma, Tarragona, Valencia
2019-03-01
Active, closed
Novartis Pharmaceuticals
Phase 2
248
Granada, Sabadell, Manises, Barcelona, Las Palmas GC, Valencia
2019-02-27
Active, closed
Acerta Pharma BV
Phase 3
984
Badalona, Barcelona, Madrid, Majadahonda, Salamanca, Santander, Valencia
2019-02-25
Active, closed
AbbVie
Phase 1
364
Pamplona, Barcelona, Madrid, Valencia
2019-02-21
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo
2019-02-08
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
Seville, Badalona, Pamplona, Barcelona, Granada, Madrid, Málaga, Valencia
2019-01-30
Active, closed
AstraZeneca
Phase 2
367
Córdoba, Donostia / San Sebastian, Madrid, Málaga, Valencia, Zaragoza
2019-01-09
Active, closed
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
DrugsCCNU·Lomustine·Abraxane·Adriamycin
Actuate Therapeutics Inc.
Phase 2
350
Barcelona, Madrid, Valencia
2019-01-04
Recruiting
Fundación Academia Española de Dermatología
Observational
2,500
Badalona, Alicante, Barcelona, Las Palmas, Madrid, Pontevedra, Valencia, Zaragoza
2019-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Lugo, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Valencia
2018-12-24
Active, closed
Travere Therapeutics, Inc.
Phase 3
406
Palma de Mallorca, Sagunto, Barcelona, Madrid, Seville, Valencia, Zaragoza
2018-12-11
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
A Coruña, Barcelona, Elche, Madrid, Málaga, Pamplona, Valencia
2018-11-28
Active, closed
AstraZeneca
Phase 1
396
Barcelona, Madrid, Seville, Valencia
2018-10-11
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Badalona, Barcelona, Salamanca, Valencia
2018-10-04
Active, closed
AstraZeneca
Phase 3
730
Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza
2018-09-27
Active, closed
V-Wave Ltd
Not applicable
605
Barcelona, Madrid, Valencia, Valladolid
2018-09-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Donostia / San Sebastian, Valencia, Barcelona, Madrid, Seville
2018-09-12
Active, closed
Hoffmann-La Roche
Phase 3
257
Barcelona, Madrid, Seville, Valencia
2018-08-16
Recruiting
Sanofi
Phase 2
51
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Valencia
2018-08-09
Active, closed
AstraZeneca
Phase 3
216
Barcelona, Madrid, Málaga, San Sebastián, Seville, Valencia
2018-07-19
Active, closed
Myocardial FIbrosis in Repaired Tetralogy of FAllot- FIFA Study)
NCT04737135Congenital Heart Disease, Congenital Heart Defect, Fallot Tetralogy
Hospital Universitari Vall d'Hebron Research Institute
Observational
224
Madrid, Barcelona, Seville, Valencia
2018-07-09
Active, closed
Memorial Sloan Kettering Cancer Center
Phase 3
732
Oviedo, Madrid, Barcelona, Castellon, Seville, Valencia
2018-06-19
Active, closed
Exelixis
Phase 3
837
Santander, Majadahonda, Pamplona, Barcelona, Madrid, Valencia, Zaragoza
2018-06-10
Active, closed
Genentech, Inc.
Phase 1
123
Pozuelo de Alarcón, Barcelona, Madrid, Valencia
2018-06-06
Active, closed
Canadian Cancer Trials Group
Phase 2
129
Pamplona, Barcelona, Madrid, Valencia
2018-05-28
Active, closed
Hoffmann-La Roche
Phase 3
927
Barcelona, Murcia, Valencia
2018-05-28
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Alicante, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Valencia, Vigo
2018-05-14
Active, closed
Hoffmann-La Roche
Phase 1/2
211
Barcelona, Madrid, Málaga, Valencia
2018-05-08
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
DrugPetosemtamab
Merus B.V.
Phase 1/2
560
Barcelona, Madrid, Pamplona, Valencia
2018-05-02
Active, closed
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
NCT03569241Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Cancer
University Hospital, Ghent
Phase 2
196
Barakaldo, Bilbao, Madrid, Navarro, Santiago, Valencia
2018-04-27
Active, closed
MedImmune LLC
Phase 1
400
A Coruña, Barcelona, Majadahonda, Málaga, Pamplona, Valencia
2018-04-24
Active, closed
Bristol-Myers Squibb
Phase 3
545
Barcelona, Córdoba, Donostia / San Sebastian, Madrid, Pamplona, Sabadell (Barcelona), Seville, Valencia
2018-04-18
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
L'Hospitalet de Llobregat, Castellon, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Valencia
2018-04-17
Active, closed
Y-mAbs Therapeutics
Phase 2
122
Barcelona, Madrid, Seville, Valencia
2018-04-03
Active, closed
Eli Lilly and Company
Phase 3
533
Barcelona, Seville, Valencia, Valladolid
2018-03-14
Active, closed
AstraZeneca
Phase 2
273
Barcelona, Cáceres, Madrid, Palma de Mallorca, San Sebastián, Sant Cugat del Vallès, Seville, Valencia
2018-03-07
Recruiting
Octapharma
Observational
200
Alicante, Barcelona, Málaga, Palma de Mallorca, Valencia
2018-02-13
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Barcelona, Madrid, Valencia
2018-01-26
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Valencia
2018-01-02
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
DrugTabelecleucel
Pierre Fabre Medicament
Phase 3
115
Badalona, Barcelona, Santander, Madrid, Seville, Valencia
2017-12-29
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
61
Badalona, Madrid, Málaga, Salamanca, Valencia
2017-12-01
Active, closed
Genentech, Inc.
Phase 1
181
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2017-11-24
Active, closed
BeiGene
Phase 3
590
Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Valencia, Zaragoza
2017-10-31
Recruiting
Italfarmaco
Phase 2/3
206
Esplugues de Llobregat, Barcelona, Seville, Valencia
2017-10-24
Recruiting
Apollomics Inc.
Phase 2
497
Badalona, Barcelona, Madrid, Valencia
2017-09-27
Active, closed
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
Checkpoint Therapeutics, Inc.
Phase 1
272
Barcelona, Madrid, Málaga, Pamplona, San Cristóbal de La Laguna, Seville, Valencia
2017-09-20
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Barcelona, Madrid, Murcia, Pamplona, Seville, Valencia
2017-09-20
Active, closed
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
NCT03260023HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
DrugAvelumab
Transgene
Phase 1/2
143
Badalona, Granada, Madrid, Málaga, Valencia
2017-09-01
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Donostia / San Sebastian, Barcelona, Madrid, Seville, Valencia
2017-08-23
Active, closed
Asthma Research in Children and Adolescents
NCT04480242Persistent Asthma, Asthma in Children, Asthma Exacerbation
Parc de Salut Mar
Observational
525
Cadiz, Seville, Zaragoza, Alava, Torrelavega, Barcelona, Madrid, Valencia
2017-07-26
Recruiting
Prostate Cancer Clinical Trials Consortium
Observational
5,000
Barcelona, Málaga, Valencia, Badalona, Castellon, Madrid, Oviedo, Zaragoza
2017-07-21
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Santiago de Compostela, Palma de Mallorca, Badalona, Las Palmas de Gran Canaria, Barcelona, Madrid, Seville, Valencia
2017-06-26
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Barcelona, Madrid, Murcia, Salamanca, Seville, Valencia
2017-06-26
Active, closed
Molecular and Histological Characteristics of Serrated Lesions of the Colon
NCT03089268Colonic Neoplasms, Colorectal Cancer, Sessile Serrated Adenoma, Polyp of Colon
Hospital Universitario La Fe
Observational
700
Valencia
2017-06-01
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
4,975
L'Hospitalet de Llobregat, Barcelona, Elche, Girona, Madrid, Málaga, Valencia, Valladolid
2017-05-03
Active, closed
Acerta Pharma BV
Phase 3
635
Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Seville, Valencia
2017-04-05
Active, closed
AstraZeneca
Phase 3
987
A Coruña, Badajoz, Badalona, Barcelona, Madrid, Santander, Valencia, Zaragoza
2017-03-27
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
A Coruña, Barcelona, Madrid, Santander, Seville, Valencia
2017-03-24
Recruiting
Italian Sarcoma Group
Not applicable
100
Barcelona, Madrid, Seville, Valencia
2017-03-16
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Barcelona, Madrid, Pamplona, Valencia
2017-03-07
Active, closed
European Association of Urology Research Foundation
Observational
1,054
Barcelona, Granada, Madrid, Murcia, San Cristóbal de La Laguna, Valencia
2017-02-22
Active, closed
AbbVie
Phase 1
163
Majadahonda, Madrid, Valencia
2017-02-22
Active, closed
Acerta Pharma BV
Phase 3
310
Badalona, Madrid, Majadahonda, Salamanca, Santander, Valencia
2017-02-02
Active, closed
AbbVie
Phase 3
443
Pamplona, Barcelona, Madrid, Málaga, Valencia
2017-02-02
Active, closed
ITM Solucin GmbH
Phase 3
324
Barcelona, Madrid, Oviedo, Valencia
2017-02-02
Active, closed
Genentech, Inc.
Phase 1
200
Barcelona, Valencia
2016-12-13
Active, closed
Target PharmaSolutions, Inc.
Observational
10,000
Madrid, Pamplona, Santander, Seville, Valencia
2016-12
Active, closed
Janssen Research & Development, LLC
Phase 1/2
234
Badalona, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia
2016-11-21
Active, closed
Eli Lilly and Company
Phase 1
223
Barcelona, Madrid, Valencia
2016-11-21
Active, closed
Celgene
Phase 1/2
466
Badalona (Barcelona), Barcelona, Madrid, Pamplona, Valencia
2016-10-14
Active, closed
Eisai Inc.
Phase 3
1,069
Santander, Barcelona, Cáceres, Córdoba, Madrid, Oviedo, Seville, Valencia
2016-10-13
Active, closed
Eli Lilly and Company
Phase 2
234
Barcelona, Madrid, Valencia
2016-09-14
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2
472
Barcelona, Madrid, Valencia
2016-08-03
Active, closed
Celgene
Phase 1/2
130
Barcelona, Cáceres, Madrid, Málaga, Valencia
2016-06-03
Active, closed
Geron Corporation
Phase 2/3
289
Cadiz, Majadahonda, Seville, Valencia, Barakaldo, Badalona, Barcelona, Madrid
2016-01-12
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Esplugues, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia
2015-11-02
Active, closed
Eli Lilly and Company
Phase 3
545
Barcelona, Hospitalet, Palma, Pozuelo de Alarcón, Madrid, Pamplona, Seville, Valencia
2015-05-06
Active, closed
Hoffmann-La Roche
Phase 3
154
L'Hospitalet de Llobregat, Santander, San Cristóbal de La Laguna, Bilbao, Barcelona, Valencia
2015-02-02
Active, closed
Instituto de Investigacion Sanitaria La Fe
Observational
300
Valencia
2015-01-01
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
DrugBispecific
Partner Therapeutics, Inc.
Phase 2
250
Barcelona, Madrid, Pamplona, Valencia
2015-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Alcorcón, Barcelona, Cadiz, Córdoba, Madrid, San Sebastián de los Reyes, Valencia
2014-11-26
Active, closed
Eli Lilly and Company
Phase 3
493
Badajoz, Barcelona, Donostia / San Sebastian, Lleida, Madrid, Valencia
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Valencia
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Elche, Barcelona, Lleida, Madrid, Murcia, Valencia
2014-07-22
Recruiting
Fundación Instituto Valenciano de Oncología
Observational
946
Valencia
2014-07
Recruiting
The European Paediatric Network for Haemophilia Management ( PedNet Registry)
NCT02979119Factor VIII Deficiency, Factor IX Deficiency
PedNet Haemophilia Research Foundation
Observational
4,000
Barcelona, Madrid, Seville, Valencia
2014-06
Recruiting
Jules Bordet Institute
Not applicable
1,000
A Coruña, Barcelona, Castellon, Cáceres, Lleida, Madrid, Seville, Valencia
2014-04
Recruiting
Boston Scientific Corporation
Observational
1,500
Barcelona, Madrid, Murcia, Oviedo, Valencia
2014-03-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Madrid, Seville, Valencia
2013-10-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Barcelona, Córdoba, Girona, Madrid, Pamplona, Valencia
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Barcelona, Córdoba, Hospitalet deLlobregat(Barcelo, Madrid, Valencia
2013-08-26
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Vigo, Barakaldo, Madrid, Málaga, Seville, Valencia
2013-07-26
Active, closed
Bristol-Myers Squibb
Observational
800
Sant Joan Despí, Barcelona, Madrid, Murcia, Valencia
2013-01-30
Recruiting
Boston Scientific Corporation
Observational
4,800
Ciudad Real, Madrid, Pamplona, San Sebastián, Santander, Toledo, Valencia
2012-11-19
Recruiting
CHDI Foundation, Inc.
Observational
35,000
Badajoz, Barakaldo, Barcelona, Burgos, Madrid, Palma de Mallorca, Pamplona, Valencia
2012-07
Active, closed
Sentinel Node Vs Observation After Axillary Ultra-souND
NCT02167490Early Stage Breast Carcinoma
European Institute of Oncology
Not applicable
1,560
Valencia
2012-01
Active, closed
University Medical Center Groningen
Phase 3
920
Barcelona, L'Hospitalet de Llobregat, Valencia
2011-06-21
Active, closed
AstraZeneca
Phase 2
162
Madrid, Valencia
2010-02-04
Active, closed
Australasian Gastro-Intestinal Trials Group
Phase 2/3
574
L'Hospitalet de Llobregat, Badalona, Barcelona, Valencia
2009-09
Recruiting
Esteve Pharmaceuticals, S.A.
Observational
500
Barcelona, Bilbao, Reus, Valencia
2008-12-09
Active, closed
Comparison of Three Treatment Strategies for Traumatic AO Type A1 Vertebral Fractures
NCT07471568Traumatic Vertebral Fractures, Compression Fractures of the Spine, AO Type A1 Vertebral Fracture, Spinal Trauma
University of Valencia
Observational
146
Valencia
2007-03-01
Recruiting
Fundación Instituto Valenciano de Oncología
Observational
400
Valencia
2004-04
By invitation
Copenhagen University Hospital, Rigshospitalet
Observational
23,000
Badalona, Barcelona, Madrid, Valencia, Vitoria-Gasteiz
1994-01
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
A Coruña, Barcelona, Alcorcón, Vigo, Seville, Madrid, Sabadell, Valencia
1991-04-01
Rows per page Showing 1001–1215 of 1215
Previous 1 2 3
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/valencia?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,215 of those studies with a site in Valencia.

How many clinical trials are recruiting in Valencia?

621 of the 1,215 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 43 have not yet opened recruitment, 517 are active but closed to new participants, and 34 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.